

Deliver a clot even when your patient can't.[1]

ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

Shaping the future of surgery

VeraSeal™ Fibrin Sealant (Human)

Patient factors increase **the risk of surgical bleeding**[3]



Consequences of **postoperative bleeding**

The risk of potential bleeding complications calls for a reliable fibrin clot that is effective independent of the patient coagulation profile – **especially in high-risk patients**.[3,4]

Postoperative bleeding lengthens hospital stays by **nearly 4 days** and adds **over $21K** in total cost, and unfortunately some of these cases **may be fatal**.[5]

VERASEAL Fibrin Sealant

The next-generation device

VERASEAL mimics the clot formation process regardless of patient's coagulation profile.[1,2]

VERASEAL contains **human fibrinogen** and **human thrombin**.[1] Formation of the VERASEAL fibrin clot begins to form as soon as the biologics mix.[1]

When applied to the surgical site, these biologic components generate a cross-linked fibrin clot in a process that recreates the last stage of the coagulation cascade...

...and is effective even in heparinized patients.[1]

THERAPEUTIC INDICATIONS

VERASEAL is indicated as supportive treatment in adults where standard surgical techniques are insufficient:
– for improvement of haemostasis.
– as suture support in vascular surgery.

VERASEAL provides a **rapid, adherent, and durable clot** at the bleeding site[2]

Proven sustained haemostasis[1]

Durable haemostasis demonstrated in over 300 patients across randomized controlled trials[1†‡§]

VERASEAL demonstrated a **significant reduction in time to haemostasis** compared to the control arm for vascular and parenchyma surgery in pivotal trials.[1†‡]

Safety and efficacy were evaluated in patients with a **wide range of coagulation profiles.**[1]



CONTRAINDICATIONS

VERASEAL must not be applied intravascularly.
Hypersensitivity to the active substance or to any of the excipients listed in SmPC.
VERASEAL must not be used for the treatment of severe or brisk arterial bleeding.
Spray application of VERASEAL must not be used in endoscopic (intraluminal) procedures.

Please see page 11 for important safety information. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference SmPC.

† Safety and efficacy were evaluated in vascular surgery vs manual compression. VERASEAL was shown to be superior to the control group in achieving haemostasis by 4 minutes.
‡ Safety and efficacy were evaluated in parenchyma surgery vs oxidized regenerated cellulose. VERASEAL was shown to be superior to the control group in achieving haemostasis by 4 minutes.
§ Safety and efficacy were evaluated in soft tissue surgery vs oxidized regenerated cellulose. VERASEAL was shown to be non-inferior to the control group in achieving haemostasis by 4 minutes.

No other fibrin sealant **preps faster**[10†]

No CO_2 needed
Airless Spray Technology eliminates the need for external spraying equipment

Once thawed
no additional warming needed vs TISSEEL
(4 minutes to warm)[1,11‡]

Pre-filled syringes
with click-on dual applicator, all in one box



WARNINGS AND PRECAUTIONS
For epilesional use only. Do not apply intravascularly.
Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly.

† Based on number of set-up steps and thawing time required for VERASEAL™ Dual Applicator vs competition.
‡ Refers to 10 mL TISSEEL device.

Designed for **performance**

Flexibility to drip or spray – narrow to broad

Malleable tip provides precise application to challenging anatomy

Broader range of working temperature for clinical use (2°C to 37°C) vs TISSEEL (33°C to 37°C)[1,11]



WARNINGS AND PRECAUTIONS
VERASEAL spray application should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy.
When using accessory tips, the instructions for use of the tips should be followed.

Please see page 11 for important safety information. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference SmPC.

Airless Spray Technology

Spraying with VERASEAL enables **more precise coverage** of the target tissue vs gas-assisted spray.[6,8]

VERASEAL™ Dual Applicator is designed to provide **enhanced spraying control** vs gas-assisted spray.[6,7]

Application precautions

- Before administration of VERASEAL, protect (cover) parts of the body outside the desired application area to prevent tissue adhesion at undesired sites.[1]
- Apply VERASEAL as thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.[1]
- Only spray VERASEAL if it is possible to accurately judge the distance from the spray tip to the tissue surface.[1]

WARNINGS AND PRECAUTIONS

Before administration of VERASEAL, care must be taken that the parts of the body outside the desired application area are sufficiently protected (covered) to prevent tissue adhesion at undesired sites.

VERASEAL should be applied as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.

VERASEAL™ Laparoscopic Dual Applicators for your **minimally invasive procedures**

The malleable Dual Applicators are offered as 35 cm Rigid and 45 cm Flexible tips and can be used for spraying or dripping. Each comes with an airless spray tip attached and 2 replacement airless spray tips.

VERASEAL™ Laparoscopic Dual Applicators are sold separately, 3 per box, along with 3 airless spray tips.

WARNINGS AND PRECAUTIONS

As with any protein product, allergic type hypersensitivity reactions are possible.

When medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions (reported in >1% of clinical trial subjects) were nausea and procedural pain.

Please see page 11 for important safety information. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference SmPC.

Ordering information

VRA04SG 1 x 4 mL Device

VRA10SG 1 x 10 mL Device

VRAL35
3 x 35 cm Lap (Rigid)

VRAL45
3 x 45 cm Lap (Flex)

VERASEAL™ Fibrin Sealant (Human) IMPORTANT SAFETY INFORMATION

THERAPEUTIC INDICATIONS

VERASEAL is indicated as supportive treatment in adults where standard surgical techniques are insufficient:
- for improvement of haemostasis.
- as suture support in vascular surgery.

CONTRAINDICATIONS

VERASEAL must not be applied intravascularly.

Hypersensitivity to the active substance or to any of the excipients listed in SmPC.

VERASEAL must not be used for the treatment of severe or brisk arterial bleeding.

Spray application of VERASEAL must not be used in endoscopic (intraluminal) procedures.

WARNINGS AND PRECAUTIONS

For epilesional use only. Do not apply intravascularly.

Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly.

VERASEAL spray application should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy.

When using accessory tips, the instructions for use of the tips should be followed.

Before administration of VERASEAL, care must be taken that the parts of the body outside the desired application area are sufficiently protected (covered) to prevent tissue adhesion at undesired sites.

VERASEAL should be applied as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.

As with any protein product, allergic type hypersensitivity reactions are possible.

When medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions (reported in >1% of clinical trial subjects) were nausea and procedural pain.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference SmPC.

Potential re-bleeding risk

Bleeding may be addressed intraoperatively, but could later develop into more serious complications[3,4]

VERASEAL

Part of the Ethicon **Haemostasis Optimization Program** – a systemic approach to bleeding management

The next generation device awaits you.

For more information, contact your sales representative.

References : **1.** VERASEAL™ Fibrin Sealant (Human). Full Prescribing Information. April 2019. **2.** Bjelovic M, Ayguasonosa J, Kim RD *et al.* A prospective, randomized, phase III study to evaluate the efficacy and safety of fibrin sealant Grifols as an adjunct to hemostasis as compared to cellulose sheets in hepatic surgery resections. *J Gastrointest Surg.* 2018;22:1939-1949. **3.** Marietta M, Facchini L, Pedrazzi P, Busani S, Torelli G. Pathophysiology of bleeding in surgery. *Transplant Proc.* 2006;38(3):812-814. **4.** Saif R, Jacob M, Robinson S *et al.* Use of fibrin-based sealants and gelatin-matrix hemostats in laparoscopic liver surgery. *Surg Laparosc Endosc Percutan Tech.* 2011;21(3):131-141. **5.** AHQR. Postoperative hemorrhage or hematoma (provider-level): rate per 1,000 surgical discharges. Measure Summary NQMC-8088. **6.** Completion Report for Angled Adherence, Study No. 100682576. December 10, 2018. Ethicon, Inc. **7.** Phillips R. VERASEAL ASA Design Verification Memo for Expression Force and Surface Area. 100675646 Rev 1. December 5, 2018. Ethicon, Inc. **8.** Kong W, Wang D, Geisa PC. Evaluation of the hemostatic efficacy of Grifols fibrin sealant (human) delivered by VERASEAL open delivery system using an acute swine model. Final Report PSB004796. October 17, 2018. Ethicon, Inc. **9.** Goellner KN, Sparrow E. An environmental impact comparison of single-use and reusable thermally controlled shipping containers. *Int J Life Cycle Assess.* 2014;19:611-619. **10.** Thawing time and set-up steps comparison between VERASEAL, EVICEL, and TISSEEL. Report 100708726-Rev 2. August 28, 2019. Ethicon, Inc. **11.** TISSEEL (Fibrin Sealant). Full Prescribing Information. Baxter Healthcare Corporation.

Johnson & Johnson Pte Ltd
2 Science Park Drive, The Ascent, #07-13, Singapore Science Park Drive 1, S(118222)

210087-220419
Johnson & Johnson Pte. Ltd., 2 Science Park Drive, Ascent, #07-13, Singapore Science Park 1, Singapore 118222

ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES
Shaping the future of surgery

VeraSeal™ Fibrin Sealant (Human)